Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
reaffirmed his Buy rating on Taysha Gene Therapies, assigning a $9 price target. On November 5, Truist Financial analyst Joon Lee also reaffirmed a Buy rating on Taysha Gene Therapies Inc. (NASDAQ:TSHA) following the company's third-quarter results. Taysha Gene Therapies Inc. (TSHA) Net Loss Widens But Touts FDA Milestone and Financial Strength Photo by CDC on Unsplash On November 4, Taysha Gene Therapies Inc.'s Chief Executive Officer reiterated that the company has made progress and is poised for a potentially transformative period. The company achieved significant milestones, including achieving FDA Breakthrough Designation for TSHA-102. The breakthrough Designation is of the company's flagship treatment for Rett Syndrome. Additionally, the company finalized FDA alignment on the REVEAL Pivotal Trial Protocol and SAP for TSHA-102. In addition, the company confirmed it has regained full rights to the TSHA-102 program following the expiration of a 2022 option agreement with As
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
TSHA
Earnings
- 11/4/25 - In-Line
TSHA
Sec Filings
- 12/1/25 - Form 4
- 11/28/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TSHA's page on the SEC website